medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2012, Number 4

<< Back Next >>

Acta Pediatr Mex 2012; 33 (4)

Flow cytometry for the evaluation of minimal residual disease in acute lymphoblastic leukemia

Juárez-Velázquez R, Pérez-Vera P

Language: Spanish
References: 46
Page: 198-206
PDF size: 461.92 Kb.


ABSTRACT

Detection of minimal residual disease (MRD) by flow cytometry in acute lymphoblastic leukemia is based on the identification of immunological profiles, expressed only in leukemic but not in normal cells. The aim of MRD analysis is to assess the response to treatment by detection of at least one leukemic cell in 10,000 normal cells. MRD evaluation makes it possible to identify patients with high risk of relapse, resulting in an adequate management of leukemia. This review presents an overall picture of flow cytometry features which can be applied in hematology and oncology, focus in the meaning and usefulness of MRD assessment, as well as in those aspects considered for performing it successfully.


REFERENCES

  1. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behem FG, Raimondi SC. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;15:2691-6.

  2. Ibrahim SF, van den Engh G. Flow cytometry and cell sorting. Adv Biochem Eng Biotechnol 2007;106:19-39.

  3. Bergquist PL, Hardiman EM, Ferrari BC, Winsley T. Applications of flow cytometry in environmental microbiology and biotechnology. Extremophiles 2009;13(3):389-401.

  4. Barrera R, Drago S, Perez R, Zamora AC, Arroyo F, Sainz Espuñes T y cols. Citometría de flujo: vínculo entre la investigación básica y la aplicación clínica. Rev Inst Nal Enf Resp Mex 2004;17:42-55.

  5. Pérez-Vera P, Frías S, Carnevale C, Betancourt M, Mujica M, Rivera-Luna R y cols. A strategy to detect chromosomal abnormalities in children with acute lymphoblastic leukemia. J Ped Hem/Oncol 2004;26:294-300.

  6. McCloskey TW, Oyaizu N, Coronesi M, Pahwa S. Use of a flow cytometric assay to quantitate apoptosis in human lymphocytes. Clin Immunol Immunopathol 1994;7:14-8.

  7. van der Velden VH, Szczepanski T, Wijkhuijs JM, Hart PG, Hoogeveen PG, Hop WC y cols. Age-related patterns of immunoglobulin and T-Cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia 2003;17(9):1834-44.

  8. Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A y cols. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006;12(8):2434-41.

  9. Paietta E. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?. Bone Marrow Transplant 2002;29(6):459-65.

  10. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology 2010;7-12.

  11. Koh DN, Park M, Kim BE, Im HJ, Park CJ, Jang S y cols. Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia. Korean J Pediatr 2010;53(11):957-64.

  12. Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010;22(6):656-63.

  13. van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC y cols. Clinical significance of flow cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010;24(9):1599-606.

  14. Szczepanski T. Why and How to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007;21:622-6.

  15. Campana D. Determination of minimal residual disease in leukemia patients. Br J Haematol 2003;121:823-38.

  16. Szczepanski T, van der Velden VH, van Dongen JJ. Flowcytometric immunophenotyping of normal and malignant lymphocytes. Clin Chem Lab Med 2006;44(7):775-96.

  17. Campana D. Status of minimal residual disease testing in childhood hematological malignancies. Br J Haematol 2008; 143: 481-9.

  18. Rubnitz JE, Onciu M, Pounds S, Shurtleff S, Cao X, Raimondi SC y cols. Acute mixed lineage leukemia in children: the experience of St Jude Children´s Research Hospital. Blood 2009;113:5083-9.

  19. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK y cols. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002;100(7):2399-402.

  20. Campana D y Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry (Communications in clinical Cytometry) 1999;38:139-52.

  21. Campana D. Molecular determinants of treatment response in acute lymphoblastic leukemia. Acute lymphoblastic leukemia. Haematol Am Soc Hematol Educ Program 2008;366-73.

  22. Jółkowska J, Derwich K, Dawidowska M. Methods of minimal residual disease (MRD) detection in childhood hematological malignancies. J Appl Genet 2007;48(1):77-83.

  23. Campana D. Minimal Residual Disease studies in acute leukemia. Am J Clin Pathol 2004;122(Suppl 1):S47-S57.

  24. Longacre TA, Foucar K, Crago S, Chen IM, Griffith B, Dressler L y cols. Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood 1989;73(2):543-52.

  25. Caldwell CW, Patterson WP. Relationship between CD45 antigen expression and putative stages of differentiation in B-cell malignancies. Am J Hematol 1991;36(2):111-5.

  26. Lucio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E y cols. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999;13(3):419-27.

  27. van Lochem EG, Wiegers YM, van den Beemd R, Hählen K, van Dongen JJ, Hooijkaas H. Regeneration patterns of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia 2000;14(4):688-95.

  28. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotipic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4 color flow cytometry. Blood 2001;98(8):2498-507.

  29. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S y cols. Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. Br J Haematol 2003;123(2):243-52.

  30. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T y cols. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia 2001;15(8):1185-92.

  31. Porwit-MacDonald A, Björklund E, Lucio P, van Lochem EG, Mazur J, Parreira A y cols. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000;14(5):816-25.

  32. Muzzafar T, Medeiros LJ, Wang SA, Brahmandam A, Thomas DA, Jorgensen JL. Aberrant under expression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol 2009;132(5):692-8.

  33. Coustan-Smith E, Ribeiro RC, Stow P, Zohu Y, Pui CH, Rivera GK y cols. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006;108(1):97-102.

  34. Boublikova L, Kalinova M, Ryan J, Quinn F, O´Marcaigh A, Smith O y cols. Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006;20(2):254-63.

  35. Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P y cols. WT1 protein expression in childhood acute leukemia. Am J Hematol 2008;83(5):382-6.

  36. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23(5):1083-98.

  37. Neale GA, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P y cols. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999;13(8):1221-6.

  38. Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA y cols. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000;95(3):815-9.

  39. Tobal K, Moore H, Macheta M, Yin JA. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RAR alpha transcripts with a sensitive competitive RTPCR method. Leukemia 2001;15(7):1060-5.

  40. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC y cols. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96(8):2691-6.

  41. Ruiz-Argüelles G, Fernández-Lara, Estrada-Gomez R, Manzano C, Ruiz-Delgado GJ, Pérez-Romano B y cols. Minimal Residual Disease Testing in Acute Leukemia by Flow Cytometry Inmmunophenotyping: Prognostic Significance. Lab Hematol 2007;13:22-6.

  42. Coustan-Smith E, Gajjar A, Hijiya N, Razzouk BI, Ribeiro RC, Rivera GK y cols. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004;18(3):499-504.

  43. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC y cols. Immunological detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet 1998;351:550-4.

  44. Dworzak MN, Fröschl G, Printz D, Mann G, Pötschger U, Mühlergger N y cols. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99(6):1952-8.

  45. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL y cols. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008;111(12):5477-85.

  46. Sánchez J, Serrano J, Gomez P, Martinez F, Martin C, Madero L y cols. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukemia after allogeneic transplantation. Br J of Haematol 2002;116:686-94.




2020     |     www.medigraphic.com